STRO

#2800
Sutro Biopharma, Inc.
35.8000 USD
+6.58%
부문: 헬스케어
베이스: USD
수익 통화: USD
일일 변동 비율
35.6777
35.9500
년간 변동
16.7400
36.0000
일일 변동
+6.58%
월간 변동
+46.54%
6달 변화
+105.87%
년간 변동율
+105.87%
이전 종가
33.5900
시가
35.9500
저가
35.6777
High
35.9500
양
5
전체 차트 열기

Financials

개요 성명 통계
4분기 연간
  • Market Capitalization 593.1071 M
  • Employee 137
  • Founded 2003
  • CEO N/A
  • Website www.sutrobio.com
  • Headquarter California, United States
  • FIGI BBG000R4V3P3
  • Industry 생명공학
총매출
순이익
주당 순이익(기본 EPS)
총부채
잉여 현금 흐름
현금 및 현금성 자산
주가수익비율
-0.51
주가매출액비율
0.96

Sutro Biopharma Inc

Sutro Biopharma, Inc. is a publicly traded biotechnology company headquartered in South San Francisco, California focused on clinical-stage drug discovery, development and manufacturing. Using a proprietary cell-free protein synthesis platform, Sutro is working on oncology therapeutics using protein engineering and rational design. Founded in 2003 under the name Fundamental Applied Biology, the company name changed to Sutro Biopharma in 2009. William Newell, CEO as of 2024, joined Sutro in January 2009. Sutro's cell-free protein synthesis and site-specific conjugation platform, XpressCF+, contributed to the discovery of STRO-001 and STRO-002, internally-developed antibody drug conjugates, or ADCs. STRO-001 is an ADC targeting CD74, a protein highly expressed in multiple myeloma and non-Hodgkin's lymphoma, and is currently in a Phase I clinical trial. STRO-002 is an ADC targeting folate receptor alpha, a cell-surface protein highly expressed in gynecological cancers.

뉴스